Chondrosarcoma Pipeline Analysis (H2 2018) – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

Chondrosarcoma Pipeline Analysis (H2 2018) – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

Chondrosarcoma Pipeline Analysis report covers drugs of 10 companies currently in different phases of development. Chondrosarcoma is rare cancer which usually develops in bones and soft tissues surrounding them. There are two types of Chondrosarcoma: primary chondrosarcoma and secondary chondrosarcoma. The disease symptoms occur right in the area of tumor or the area surrounding the tumors which may include pain that gradually worsens, large lump formation on the bone, stiffness, swelling, tenderness, a feeling of pressure around the tumor. Diagnosis of the disease is done using a physical exam, imaging tests, and biopsy. Treatment options include surgery and radiation therapy.

The report provides chondrosarcoma treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Aadi Bioscience, Inc., Agios Pharmaceuticals, Inc., Celgene Corporation, Bristol-Myers Squibb, and Idera Pharmaceuticals, Inc. among others.

Scope:

By Company

By Phase

By Molecule Type

By Region

By Route of Administration

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target 
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Aadi Bioscience, Inc.
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Agios Pharmaceuticals, Inc.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Celgene Corporation
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Bristol-Myers Squibb
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. DAIICHI SANKYO COMPANY, LIMITED
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Epizyme, Inc.
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Idera Pharmaceuticals, Inc.
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Forma Therapeutics, Inc. 
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Merck & Co., Inc.
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Nektar Therapeutics
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
List of Tables
List of Figures

Aadi Bioscience, Inc.

Agios Pharmaceuticals, Inc.

Celgene Corporation

Bristol-Myers Squibb

DAIICHI SANKYO COMPANY, LIMITED

Epizyme, Inc.

Idera Pharmaceuticals, Inc.

Forma Therapeutics, Inc. 

Merck & Co., Inc.

Nektar Therapeutics

  • SKU:
  • Publishing Date: 2018-05-15
  • Product Code: 1
  • Availability: In Stock
  • $2,400.00
  • Ex Tax: $2,400.00

Available Options